Review
doi: 10.3949/ccjm.69.10.761.
The newer antimuscarinic drugs: bladder control with less dry mouth
Affiliations
- PMID: 12371799
- DOI: 10.3949/ccjm.69.10.761
Item in Clipboard
Review
The newer antimuscarinic drugs: bladder control with less dry mouth
Cleve Clin J Med.
2002 Oct.
Free article
Abstract
Two newer antimuscarinic anticholinergic drugs--tolterodine and extended-release oxybutynin--are approximately as effective in treating overactive bladder as immediate-release oxybutynin, but are more tolerable. I review clinical trial data on the newer agents.
Similar articles
-
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.Int Urol Nephrol. 2005;37(2):247-52. doi: 10.1007/s11255-004-4703-7. Int Urol Nephrol. 2005. PMID: 16142551 Clinical Trial.
-
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687. Mayo Clin Proc. 2003. PMID: 12934777 Clinical Trial.
-
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).Curr Med Res Opin. 2002;18(4):177-84. doi: 10.1185/030079902125000570. Curr Med Res Opin. 2002. PMID: 12201616 Clinical Trial.
-
Tolterodine: a clinical review.J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. doi: 10.1089/15246090152636488. J Womens Health Gend Based Med. 2001. PMID: 11703885 Review.
-
Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Indian J Physiol Pharmacol. 2013. PMID: 24968572
Cited by
-
Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.Pharmacoeconomics. 2005;23(10):995-1006. doi: 10.2165/00019053-200523100-00003. Pharmacoeconomics. 2005. PMID: 16235973 Review.
-
Social, economic, and health utility considerations in the treatment of overactive bladder.Open Access J Urol. 2010 Feb 11;2:11-24. doi: 10.2147/rru.s4166. Open Access J Urol. 2010. PMID: 24198609 Free PMC article. Review.
-
Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed.Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E88-92. doi: 10.5489/cuaj.269. Can Urol Assoc J. 2013. PMID: 23671514 Free PMC article.
-
Oxybutynin extended release and tolterodine immediate release : a health economic comparison.Clin Drug Investig. 2004;24(2):81-8. doi: 10.2165/00044011-200424020-00003. Clin Drug Investig. 2004. PMID: 17516694
-
Lesions in the oral cavity and esophagus caused by prescribed drugs: A review.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Mar;166(1):21-27. doi: 10.5507/bp.2021.059. Epub 2021 Nov 5. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. PMID: 34747416 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
